The Development of a Floating Drug-Delivery System for Metronidazole - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

The Development of a Floating Drug-Delivery System for Metronidazole
The authors developed a metronidazole-based floating drug-delivery system to investigate the effect of rate-controlling polymers on release pattern and duration of buoyancy in matrix tablets.


Pharmaceutical Technology
pp. 41-44

References

1. A.A. Deshpande et al., Pharm. Res. 14 (6), 815–819 (1997).

2. F. Stops et al., Int. J. Pharm. 308 (1–2), 8–13 (2006).

3. F. Stops et al., Int. J. Pharm. 308 (1–2), 14–24 (2006).

4. S.C. Sweetman, "Biowaiver Monographs for Immediate Release Solid Oral Dosage Forms: Metronidazole," in The Complete Drug Reference, C.F. Rediguieri et al., Eds. (Pharmaceutical Press, London, 36th ed., 2009), pp. 837–841.

5. J.S. Simms-Cendan, J. Infect. Dis. 3 (5), 153–156 (1996).

6. J.W. Tracy and L.T. Webster, Jr., "Drugs Used in the Chemotherapy of Protozoal Infections," in The Pharmacological Basis of Therapeutics, J.G. Hardman, L.E. Limbird, and A.G. Gilman, Eds. (McGraw-Hill, New York, 10th ed., 2001), pp. 1105–1109.

7. K.C. Lamp et al., Clin. Pharmacokinet. 36 (5), 353–373 (1999).

8. E.D. Ralph et al., Antimicrob. Agents Chemother. 6 (6), 691–696 (1974).

9. B.N. Singh and K.H. Kim, J. Control Release 63 (3), 235–259 (2000).

10. S. Burton et al., J. Pharm. Pharmacol. 47 (11), 901–906 (1995).

11. V. Alvisi et al., Drugs Exp. Clin. Res. 22 (1), 29–33 (1996).

12. M. Rahman et al., J. Pharmaceutics Cosmetol. 1 (2), 81–92 (2011).

13. M.D. Chavanpatil et al., Int. J. Pharm. 316 (1–2), 86–92 (2006).

14. T. Higuchi, J. Pharm. Sci. 52 (12), 1145–1149 (1963).

15. S. Asnaashari et al., Pharm. Dev. Technol. 16 (4), 1–8 (2010).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
28%
Oversee medical treatment of patients in the US.
9%
Provide treatment for patients globally.
9%
All of the above.
41%
No government involvement in patient treatment or drug development.
13%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: Pharmaceutical Technology,
Click here